Dallas, Texas 07/10/2013 (Financialstrend) – The shares of Eli Lilly & Co. (NYSE:LLY) are currently trading at $51.44, stock decreased by 0.75%. The shares opened at $51.78. The intrange of the stock is between $51.25 – 51.91. The market capitalization of the stock is $57.79 billion.
Eli Lilly & Co. (NYSE:LLY) is into discovering, developing, manufacturing, and selling of pharmaceutical products. It operates in business segment of animal health. The Company carries out the manufacturing and distribution of the products by means of services in the Puerto Rico, United States, and other fifteen countries. The products of the Company are presently selling in almost 130 countries. The products of the Company consist of endocrinology products, neuroscience products, oncology products, animal health products, cardiovascular products, and several other pharmaceuticals.
THE UBS AG’s investment analysts reduced the price objective set by them on the stock of Eli Lilly & Co. (NYSE: LLY). Previously, the price of the stock was set at $55.00 and now it has been lowered down to $52.00 in Tuesday’s note issued to investors. At present, there is rating of “neutral” on the stock.
Various research reports have studied Eli Lilly & Co. (NYSE: LLY). ON June 24, through a research note to investors, Jefferies Group’s analysts restated rating of “hold” on stock of Eli Lilly & Co. (NYSE: LLY). Presently, the price target is set at $49.00 on the stock. Independently, The Street’s analysts restated a rating of “buy” on stock of Eli Lilly & Co. (NYSE: LLY) on June 20 through an investor’s research note. Sanford C. Bernstein’s analysts restated a rating of “outperform” Eli Lilly & Co. (NYSE: LLY)’s shares on June 14, through an investor’s research note. They have set a price target of $62.00 on the stock.
